WAYNE, Pa., Feb. 28, 2018 -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biopharmaceutical company focused on identifying, developing, and commercializing innovative and differentiated therapies to address significant unmet needs in medical and aesthetic dermatology, will report financial results for the fourth quarter and year ending December 31, 2017 on Monday, March 12, 2018, before the U.S. financial markets open.
Management will provide an update on the Company and discuss fourth quarter and year-end 2017 results as well as expectations for the future via conference call on Monday, March 12, 2018, at 8:00 AM ET. To participate on the live call, please dial (844) 776-7782 (domestic) or (661) 378-9535 (international), and reference conference ID 1495576 prior to the start of the call.
A live webcast of the event can be accessed on the Events and Presentations page on the Investors section of the Aclaris website at http://www.aclaristx.com/events-and-webcasts. A replay of the webcast will be archived on the Aclaris website following the event.
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. is a dermatologist-led biopharmaceutical company committed to identifying, developing and commercializing innovative therapies to address significant unmet needs in aesthetic and medical dermatology and immunodermatology. The Company is focused on market segments with no FDA-approved medications or where treatment gaps exist. Aclaris is based in Wayne, Pennsylvania and more information about the company can be found by visiting the Aclaris website at www.aclaristx.com.
Contact:
Aclaris Contact
Michael Tung, M.D.
Senior Vice President / Corporate Strategy / Investor Relations
484-329-2140
[email protected]
Media Contact
Laura Morgan
TogoRun
347-342-8496
[email protected]


Meta Ordered to Pay $567M Over Child Safety Violations in New Mexico
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook
Berkshire Hathaway Cash Falls as Abel Boosts Stock Buybacks
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns
OpenAI Restricts Astra AI Over Cyberattack Risks
Delta Flight Makes Emergency Landing in Atlanta After Cockpit Fumes Reported
Mercedes-Benz Stock Offers Deep-Value Potential as Citi Sees Recovery Catalysts 



